Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

mFOLFIRINOX Combined With Anlotinib and Sintilimab as First-Line Therapy for Locally Advanced or Metastatic Pancreatic Cancer: A Prospective, Single-arm, Multicenter, Phase Ib/II Clinical Study

NCT06761027 is registered in ClinicalTrials.gov with Fujian Provincial Hospital as lead sponsor.

NCT NCT06761027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06761027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
mFOLFIRINOX Combined With Anlotinib and Sintilimab as First-Line Therapy for Locally Advanced or Metastatic Pancreatic Cancer: A Prospective, Single-arm, Multicenter, Phase Ib/II Clinical Study
Lead sponsor
Fujian Provincial Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 23, 2024
Completion date
May 31, 2027
Enrollment
29 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic cancer, metastatic pancreatic cancer